CN103450332B - 苯乙烯-β-咔啉修饰的三肽苄酯,其制备,抗肿瘤活性和应用 - Google Patents
苯乙烯-β-咔啉修饰的三肽苄酯,其制备,抗肿瘤活性和应用 Download PDFInfo
- Publication number
- CN103450332B CN103450332B CN201210181086.3A CN201210181086A CN103450332B CN 103450332 B CN103450332 B CN 103450332B CN 201210181086 A CN201210181086 A CN 201210181086A CN 103450332 B CN103450332 B CN 103450332B
- Authority
- CN
- China
- Prior art keywords
- trp
- obzl
- carboline
- boc
- styryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 benzyl ester Chemical class 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 14
- OIHRCCBRHLOMLX-UHFFFAOYSA-N C1=NC=CC=2C3=CC=CC=C3NC12.C(=C)C1=CC=CC=C1 Chemical compound C1=NC=CC=2C3=CC=CC=C3NC12.C(=C)C1=CC=CC=C1 OIHRCCBRHLOMLX-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 71
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- VGALFAWDSNRXJK-VIFPVBQESA-N L-aspartic acid beta-benzyl ester Chemical compound OC(=O)[C@@H](N)CC(=O)OCC1=CC=CC=C1 VGALFAWDSNRXJK-VIFPVBQESA-N 0.000 claims abstract description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 61
- 125000002252 acyl group Chemical group 0.000 claims description 34
- SIJMWNIFHAIZPV-UHFFFAOYSA-N C1=NC(=CC=2C3=CC=CC=C3NC12)C(=O)O.C(=C)C1=CC=CC=C1 Chemical compound C1=NC(=CC=2C3=CC=CC=C3NC12)C(=O)O.C(=C)C1=CC=CC=C1 SIJMWNIFHAIZPV-UHFFFAOYSA-N 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- ILKGSGVTFMDFGS-UHFFFAOYSA-N 1-(2-phenylethenyl)-9H-pyrido[3,4-b]indole-3-carboxylic acid Chemical compound C(=CC1=CC=CC=C1)C1=NC(=CC=2C3=CC=CC=C3NC1=2)C(=O)O ILKGSGVTFMDFGS-UHFFFAOYSA-N 0.000 claims description 11
- 238000009833 condensation Methods 0.000 claims description 10
- 230000005494 condensation Effects 0.000 claims description 10
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 9
- TYQYRKDGHAPZRF-INIZCTEOSA-N benzyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)OCC1=CC=CC=C1 TYQYRKDGHAPZRF-INIZCTEOSA-N 0.000 claims description 7
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 claims description 6
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 6
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000007127 saponification reaction Methods 0.000 claims description 6
- WXYGVKADAIJGHB-ZDUSSCGKSA-N (2s)-3-(1h-indol-2-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2NC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CC2=C1 WXYGVKADAIJGHB-ZDUSSCGKSA-N 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 claims description 4
- COLXBVRHSKPKIE-NYVOZVTQSA-N Trp-Trp-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(O)=O COLXBVRHSKPKIE-NYVOZVTQSA-N 0.000 claims description 4
- IYHRKILQAQWODS-VJBMBRPKSA-N Trp-Trp-Glu Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IYHRKILQAQWODS-VJBMBRPKSA-N 0.000 claims description 4
- XXJDYWYVZBHELV-TUSQITKMSA-N Trp-Trp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CCCCN)C(=O)O)N XXJDYWYVZBHELV-TUSQITKMSA-N 0.000 claims description 4
- 238000007171 acid catalysis Methods 0.000 claims description 4
- 238000005899 aromatization reaction Methods 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 claims description 4
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- YIRBOOICRQFSOK-NSHDSACASA-N benzyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1=CC=CC=C1 YIRBOOICRQFSOK-NSHDSACASA-N 0.000 claims description 2
- MBRRYUQWSOODEO-LBPRGKRZSA-N benzyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OCC1=CC=CC=C1 MBRRYUQWSOODEO-LBPRGKRZSA-N 0.000 claims description 2
- VVCLBQFBKZQOAF-NSHDSACASA-N benzyl (2s)-pyrrolidine-2-carboxylate Chemical compound O=C([C@H]1NCCC1)OCC1=CC=CC=C1 VVCLBQFBKZQOAF-NSHDSACASA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 241001529936 Murinae Species 0.000 abstract description 3
- 206010039491 Sarcoma Diseases 0.000 abstract description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 72
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 60
- 239000000843 powder Substances 0.000 description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 27
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 26
- 239000007787 solid Substances 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000003756 stirring Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- ARLVFKCLBYUINL-UHFFFAOYSA-N 9h-pyrido[3,4-b]indole-3-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1C=NC(C(=O)O)=C2 ARLVFKCLBYUINL-UHFFFAOYSA-N 0.000 description 4
- 230000002112 DNA intercalation Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010029350 Neurotoxicity Diseases 0.000 description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000007135 neurotoxicity Effects 0.000 description 4
- 231100000228 neurotoxicity Toxicity 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical class [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 125000005504 styryl group Chemical group 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- NQIHMZLGCZNZBN-UHFFFAOYSA-N tryptophyl-tryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C(CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-UHFFFAOYSA-N 0.000 description 2
- 108010045269 tryptophyltryptophan Proteins 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及苯乙烯-β-咔啉修饰的三肽苄酯,其制备,抗肿瘤活性和应用,提供了通式I代表的17种化合物,提供了它们的制备方法,进一步提供了它们在肿瘤细胞模型和移植性小鼠S180肉瘤模型上的抗肿瘤作用。因而本发明提供的通式I代表的17种化合物具有作为抗肿瘤剂的临床应用前景。式中AA选自Gly,Ala,Leu,Ile,Phe,Ser,Trp,Glu(OBzl),Thr,Val,Pro,Lys(Z),Asp(OBzl),Gln,Asn,Tyr和Met。
Description
技术领域
本发明涉及了通式I代表的17个化合物,涉及它们的制备方法,进一步涉及它们它们在肿瘤细胞模型和移植性小鼠S180肉瘤模型上的抗肿瘤作用和作为抗肿瘤剂的应用,本发明属于生物医药领域。
背景技术
恶性肿瘤是全球致死率最高的病因之一。DNA嵌插剂类抗肿瘤药物以DAN为直接靶点,是临床应用的抗肿瘤药物的重要类型。临床应用的DNA嵌插剂类抗肿瘤药物虽然疗效明确,但神经毒性强。寻找疗效好,没有神经毒性的新型DNA嵌插剂是肿瘤药物研究的热点。
发明人在长期的研究中发现β-咔啉-3-羧酸不仅能够嵌插到肿瘤的DNA中,而且没有明显的神经毒性(结构1)。
发明人在长期的研究中还发现1位苯乙烯基取代的β-咔啉-3-羧酸嵌插到肿瘤的DNA中的性能比β-咔啉-3-羧酸优秀(结构2)。
发明人在长期的研究中进一步发现将1位苯乙烯基取代的β-咔啉-3-羧酸与色氨酰色氨酸苄酯偶联,可以进一步增强肿瘤DNA嵌插活性并进一步降低神经毒性(结构3)。
发明人在长期的研究中进一步发现在N-(1位苯乙烯基-β-咔啉-3-甲酰)色氨酰色氨酸苄酯中插入氨基酸,可以改善药代动力学性质(结构4)。结构4就是本发明的一系列N-(1-苯乙烯基-β-咔啉-3-甲酰)-Trp-Trp-AA-OBzl。它们的特征在于抗肿瘤作用强,毒副作用弱。
发明内容
本发明的第一个内容是提供通式I代表的17种N-(1-苯乙烯基-β-咔啉-3-甲酰)-Trp-Trp-AA-OBzl:
式中AA选自Gly,Ala,Leu,Ile,Phe,Ser,Trp,Glu(OBzl),Thr,Val,Pro,Lys(Z),Asp(OBzl),Gln,Asn,Tyr和Met.
本发明的第二个内容是提供通式I代表的17种N-(1-苯乙烯基-β-咔啉-3-甲酰)-Trp-Trp-AA-OBzl的制备方法,该方法包括:
2.权利要求1的通式I代表的17种化合物的制备,该方法由以下步骤构成:
1)在浓盐酸催化存在下Trp-OMe在甲醇中与苯丙烯醛进行Pictet-Spengler缩合生成1-苯乙烯基-1,2,3,4-四氢-β-咔啉-3-甲酯;
2)在浓盐酸催化存在下Trp-OBzl在甲醇中与苯丙烯醛进行Pictet-Spengler缩合生成1-苯乙烯基-1,2,3,4-四氢-β-咔啉-3-苄酯;
3)1-苯乙烯-1,2,3,4-四氢-β-咔啉-3-甲酯在无水THF中与二氯二氰基苯醌芳构化为1-苯乙烯基-β-咔啉-3-甲酯;
4)1-苯乙烯-1,2,3,4-四氢-β-咔啉-3-苄酯在无水THF中与二氯二氰基苯醌芳构化为1-苯乙烯基-β-咔啉-3-苄酯;
5)在二氧六环中将1-苯乙烯基-β-咔啉-3-甲酯皂化为1-苯乙烯基-β-咔啉-3-羧酸;
6)在二氧六环中将1-苯乙烯基-β-咔啉-3-苄酯皂化为1-苯乙烯基-β-咔啉-3-羧酸;
7)在DCC和HOBt存在下Boc-Trp在无水THF中与Trp-OMe缩合为Boc-Trp-Trp-OMe;
8)在甲醇中将Boc-Trp-Trp-OMe皂化为Boc-Trp-Trp;
9)在DCC和HOBt存在下在无水THF中Boc-Trp-Trp分别与Gly-OBzl,Ala-OBzl,Val-OBzl,Leu-OBzl,Ile-OBzl,Pro-OBzl,Phe-OBzl,Trp-OBzl,Ser-OBzl,Thr-OBzl,Lys(Z)-OBzl,Tyr-OBzl,Glu(OBzl)-OBzl,Asp(OBzl)-OBzl,Gln-OBzl,Asn-OBzl,Met-OBzl缩合为Boc-Trp-Trp-Gly-OBzl,Boc-Trp-Trp-Ala-OBzl,Boc-Trp-Trp-Val-OBzl,Boc-Trp-Trp-Leu-OBzl,Boc-Trp-Trp-Ile-OBzl,Boc-Trp-Trp-Pro-OBzl,Boc-Trp-Trp-Phe-OBzl,Boc-Trp-Trp-Trp-OBzl,Boc-Trp-Trp-Ser-OBzl,Boc-Trp-Trp-Thr-OBzl,Boc-Trp-Trp-Glu(OBzl)-OBzl,Boc-Trp-Trp-Lys(Z)-OBzl,Boc-Trp-Trp-Tyr-OBzl,Boc-Trp-Trp-Asp(OBzl)-OBzl,Boc-Trp-Trp-Gln-OBzl,Boc-Trp-Trp-Asn-OBzl,Boc-Trp-Trp-Met-OBzl;
10)在氯化氢-乙酸乙酯溶液中步骤10)中所得的产物分别脱除Boc生成Trp-Trp-Gly-OBzl,Trp-Trp-Ala-OBzl,Trp-Trp-Val-OBzl,Trp-Trp-Leu-OBzl,Trp-Trp-Ile-OBzl,Trp-Trp-Pro-OBzl,Trp-Trp-Phe-OBzl,Trp-Trp-Trp-OBzl,Trp-Trp-Ser-OBzl,Trp-Trp-Thr-OBzl,Trp-Trp-Glu(OBzl)-OBzl,Trp-Trp-Lys(Z)-OBzl,Trp-Trp-Tyr-OBzl,Trp-Trp-Asp(OBzl)-OBzl,Trp-Trp-Gln-OBzl,Trp-Trp-Asn-OBzl,Trp-Trp-Met-OBzl;
11)在DCC和HOBt存在下在无水THF中1-苯乙烯-β-咔啉-3-苄酯分别与步骤11)中所得的产物缩合为1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰甘氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰丙氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰缬氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰亮氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰异亮氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰脯氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰苯丙氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰色氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰丝氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰苏氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰赖氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰酪氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰谷氨酸双苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰天冬氨酸双苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰谷氨酰胺苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰天冬酰胺苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰蛋氨酸苄酯。
本发明的第三个内容是评价通式I代表的17种N-(1-苯乙烯基-β-咔啉-3-甲酰)-Trp-Trp-AA-OBzl的体外和体内抗肿瘤活性。
附图说明
图1N-(1-苯乙烯基-β-咔啉-3-甲酰)-Trp-Trp-AA-OBzl的合成路线图。i)C6H5OH,H6P4O13;ii)MeOH和SOCl2;iii)MeOH和HCl;iv)DDQ和THF;v)MeOH和4NNaOH(aq);vi)DCC,HOBt和NMM;vii)HCl/EA。
具体实施方式
为了进一步阐述本发明,下面给出一系列实施例。这些实施例完全是例证性的,它们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。
实施例1制备1-苯乙烯基-(1,2,3,4)-四氢咔啉-3-羧酸甲酯(1’)
将5.09g(20mmol)HCl·Trp-OMe溶于40ml甲醇中,加入苯丙烯醛3.96g(30mmol),搅拌均匀后加入浓盐酸催化反应,常温搅拌下反应。48h后TLC(二氯甲烷/甲醇,10∶1)检测显示HCl·Trp-OMe点消失。减压蒸馏除大部分甲醇,剩余液加入100ml饱和NaHCO3溶液,析出深黄色胶状物,加入150ml乙酸乙酯萃取,酯层饱和NaCl洗涤数次,分出酯层无水Na2SO4干燥,过滤,收集滤液,旋除乙酸乙酯,得深黄色固体。产物柱层析(石油醚/丙酮,2∶1)纯化,得到4.45g(67%)目标化合物,为黄色固体粉末。ESI-MS(m/e)333[M+H]+.
实施例2制备1-苯乙烯基-(1,2,3,4)-四氢咔啉-3-羧酸苄酯(1)
将2.94g(10mmol)Trp-OBzl溶于30ml甲醇中,加入苯丙烯醛1.98g(15mmol),搅拌均匀后加入浓盐酸催化反应,常温搅拌下反应。48h后TLC(二氯甲烷/甲醇,15∶1)检测显示Trp-OBzl点消失。减压蒸馏除大部分甲醇,剩余液加入50ml饱和NaHCO3溶液,析出深黄色胶状物,加入100ml乙酸乙酯萃取,酯层饱和NaCl洗涤数次,分出酯层无水Na2SO4干燥,过滤,收集滤液,旋除乙酸乙酯,得深黄色固体。产物柱层析(石油醚/丙酮,2∶1)纯化得到2.61g(64%)目标化合物,为黄色粉末。ESI-MS(m/e)409[M+H]+.
实施例3制备1-苯乙烯基-β-咔啉-3-羧酸甲酯(2’)
将3.32g(10mmol)1-苯乙烯-(1,2,3,4)-四氢咔啉-3-甲酯溶于15ml四氢呋喃(THF)中,将溶于15ml四氢呋喃中的4.54g二氯二氰基苯醌(DDQ)溶液滴加反应液中,常温搅拌下反应。12h后TLC(石油醚/丙酮,2∶1)检测显示1-苯乙烯-(1,2,3,4)-四氢咔啉-3-甲酯消失。减压除四氢呋喃,残留物加150ml乙酸乙酯溶解,依次用饱和NaHCO3溶液,5%NaHCO3溶液,饱和NaCl溶液洗涤三次后分出酯层,酯层无水Na2SO4干燥,过滤,收集滤液,减压除乙酸乙酯得到的固体柱层析(石油醚/丙酮,5∶1)纯化,得0.59g(18%)目标化合物,为黄色粉末。Mp118-119℃.[α]D25=-6.0(c=1.0,丙酮).ESI-MS(m/e)329[M+H]+.IR(KBr)3730.27,3269.40,3025.37,2945.89,1711.79,1628.97,1560.13,1499.67,1434.93,1351.30,1250.44,1141.10,969.84,748.23,695.83,621.30,509.84.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.34(s,1H),8.83(s,1H),8.41(d,J=4.74Hz,1H),8.03(d,J=9.45Hz,1H),7.91(d,J=9.45Hz,1H),7.82(d,J=4.53Hz,2H),7.72(d,J=4.92Hz,1H),7.64(t,J=4.32Hz,J=4.80Hz,1H),7.50(t,J=4.53Hz,J=4.62Hz,2H),7.43-7.31(m,2H),3.96(s,3H).
实施例4制备1-苯乙烯基-β-咔啉-3-羧酸苄酯(2)
按照实施例3的方法由4.08g(10mmol)1-苯乙烯-(1,2,3,4)-四氢咔啉-3-苄酯制得0.694g(17%)目标化合物,为黄色固体粉末。Mp109-111℃;[α]D25=+31.67.(c=1.0,丙酮);ESI-MS(m/e):405[M+H]+.IR(KBr):3261.06,3056.88,2950.36,1708.45,1629.20,1560.43,1498.46,1451.18,1376.64,1343.72,1248.57,1104.81,971.24,747.86,694.35,589.07,505.98,432.28.1H-NMR(300MHz,DMSO-d6):δ/ppm=12.32(s,1H),8.86(s,1H),8.49-8.38(m,1H),8.00-8.08(m,1H),7.92(d,J=9.60Hz,1H),7.80(d,J=4.50Hz,1H),7.22(t,J=4.80Hz,J=4.50Hz,1H),7.69-7.61(m,2H),7.61-7.53(m,2H),7.53-7.42(m,4H),7.42-7.26(m,3H),5.48(d,J=3.60Hz,2H).
实施例5制备1-苯乙烯基-β--咔啉-3-羧酸(3)
将3.28g(10mmol)1-苯乙烯-β--咔啉-3-甲酯或者2.04g(5mmol)1-苯乙烯-β-咔啉-3-苄酯溶于20ml甲醇中,用10NNaOH调溶液pH至14,常温下搅拌反应。10h后TLC检测显示原料点消失。用浓盐酸调反应液PH至7左右,旋除甲醇,析出黄色沉淀物,过滤得沉淀用蒸馏水充分洗涤后晾干,得黄色粉末2.86g(91%)目标化合物。Mp127-128℃.[α]D25=-11.8(c=1.0,丙酮).ESI-MS(m/e)313[M+H]-.IR(KBr)3735.48,3601.26,3440.56,3266.24,3056.59,1626.33,1564.98,1499.56,1370.85,1317.11,1245.75,854.72,749.35,702.21,655.43.1H-NMR(300MHz,DMSO-d6):δ/ppm=11.74(s,1H),8.84(s,1H),8.43(d,J=6.90Hz,1H),8.21-7.50(m,5H),7.50-6.85(m,5H).13C-NMR(75MHz,DMSO):δ/ppm=165.89,142.23,142.03,138.66,136.79,136.29,135.43,135.30,130.14,130.02,129.57,129.43,127.93,123.01,121.42,121.35,116.73,113.01.1H-NMR(300MHz,DMSO-d6):δ/ppm=11.85(s,1H),10.87(d,J=6.30Hz,2H),8.95-8.52(m,2H),8.38(t,J=9.0Hz,J=8.4Hz,1H),8.09-7.49(m,10H),7.49-6,82(m,17H),5.14(d,J=8.1Hz,2H),5.10-4.85(m,1H),4.85-4.63(m,1H),3.31-3.19(m,4H)。
实施例6制备Boc-Trp-Trp-OMe
将3.04g(10mmol)Boc-Trp溶于20ml无水THF。向得到的溶液中加入1.5g(11mmol)N-羟基苯并三氮唑(HOBT)并完全溶解。10分钟后,在冰浴下加入2.46g(12mmol)二环己基羰二亚胺(DCC)与20ml无水THF的溶液,得到反应液(I)。将2.8g(11mmol)HCl·Trp-OMe悬浮于10ml无水THF并搅拌得到反应液(II)。冰浴下将反应液(II)加入反应液(I)中并室温搅拌12h,TLC(二氯甲烷/甲醇,15∶1)显示Boc-Trp消失。反应混合物过滤除去生成的二环己基脲(DCU)。滤液减压浓缩除去THF,残留物用200ml乙酸乙酯溶解。得到的溶液依次用饱和NaHCO3水溶液洗、饱和NaCl水溶液洗、5%KHSO4水溶液洗及饱和NaCl水溶液洗。乙酸乙酯相用无水Na2SO4干燥、过滤、滤液减压浓缩至干,残留物柱层析纯化,得到4.84g(92%)目标化合物,为无色粉末。ESI-MS(m/e)505[M+H]+.
实施例7制备Boc-Trp-Trp-OBzl
按照实施例6的方法由3.04g(10mmol)Boc-Trp与3.23g(11mmol)Trp-OBzl制得5.68g(95%)目标化合物,为无色粉末。ESI-MS(m/e)581[M+H]+.
实施例8制备Boc-Trp-Trp
将2.53g(5mmol)Boc-Trp-Trp-OMe溶于20ml甲醇中,将反应液置于冰浴下并搅拌,用2NNaOH调溶液PH至14,冰浴下搅拌反应。8h后TLC(二氯甲烷/甲醇,15∶1)检测显示Boc-Trp-Trp-OMe消失。反应液用饱和KHSO4水溶液调至中性,除去混合液中的甲醇,用饱和KHSO4水溶液调溶液PH至2析出胶状物,加入150ml乙酸乙酯萃取,乙酸乙酯相用饱和NaCl水溶液洗3次后用无水Na2SO4干燥、过滤、滤液减压浓缩至干,得到2.33g(91%)目标化合物,为无色粉末。ESI-MS(m/e)488[M-H]-.
实施例9制备Boc-Trp-Trp-Gly-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与1.85g(5.5mmol)Tos·Gly-OBzl制得2.20g(69%)目标化合物,为无色粉末。ESI-MS(m/e)638[M+H]+.
实施例10制备Boc-Trp-Trp-Ala-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与1.93g(5.5mmol)Tos·Ala-OBzl制得2.90g(89%)目标化合物,为无色粉末。ESI-MS(m/e)652[M+H]+.
实施例11制备Boc-Trp-Trp-Val-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.16g(5.5mmol)Tos·Val-OBzl制得3..09g(91%)目标化合物,为无色粉末。ESI-MS(m/e)680[M+H]+.
实施例12制备Boc-Trp-Trp-Ile-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.19g(5.5mmol)Tos·Ile-OBzl制得2.71g(78%)目标化合物,为无色粉末。ESI-MS(m/e)694[M+H]+.
实施例13制备Boc-Trp-Trp-Leu-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.19g(5.5mmol)Tos·Leu-OBzl制得2.95g(85%)目标化合物,为无色粉末。ESI-MS(m/e)694[M+H]+.
实施例14制备Boc-Trp-Trp-Pro-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与1.33g(5.5mmol)HCl·Pro-OBzl制得2.74g(81%)目标化合物,为无色粉末。ESI-MS(m/e)678[M+H]+.
实施例15制备Boc-Trp-Trp-Phe-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.35g(5.5mmol)Tos·Phe-OBzl制得2.96g(93%)目标化合物,为无色粉末。ESI-MS(m/e)638[M+H]+.
实施例16制备Boc-Trp-Trp-Trp-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与1.81g(5.5mmol)HCl·Trp-OBzl制得3.45g(90%)目标化合物,为无色粉末。ESI-MS(m/e)767[M+H]+.
实施例17制备Boc-Trp-Trp-Glu(OBzl)-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.76g(5.5mmol)Tos·Glu(OBzl)-OBzl制得2.52g(63%)目标化合物,为无色粉末。ESI-MS(m/e)800[M+H]+.
实施例18制备Boc-Trp-Trp-Asp(OBzl)-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.67g(5.5mmol)Tos·Asp(OBzl)-OBzl制得3.73g(95%)目标化合物,为无色粉末。ESI-MS(m/e)786[M+H]+.
实施例19制备Boc-Trp-Trp-Asn-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与1.43g(5.5mmol)HCl·Asn-OBzl制得2.12g(61%)目标化合物,为无色粉末。ESI-MS(m/e)695[M+H]+.
实施例20制备Boc-Trp-Trp-Gln-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与1.51g(5.5mmol)HCl·Gln-OBzl制得2.10g(59%)目标化合物,为无色粉末。ESI-MS(m/e)709[M+H]+.
实施例21制备Boc-Trp-Trp-Lys(Z)-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.98g(5.5mmol)Tos·Lys(Z)-OBzl制得3.66g(87%)目标化合物,为无色粉末。ESI-MS(m/e)843[M+H]+.
实施例22制备Boc-Trp-Trp-Ser-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.02g(5.5mmol)Tos·Ser-OBzl制得2.77g(83%)目标化合物,为无色粉末。ESI-MS(m/e)668[M+H]+.
实施例23制备Boc-Trp-Trp-Thr-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.10g(5.5mmol)Tos·Thr-OBzl制得2.63g(77%)目标化合物,为无色粉末。ESI-MS(m/e)682[M+H]+.
实施例24制备Boc-Trp-Trp-Tyr-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.44g(5.5mmol)Tos·Tyr-OBzl制得3.38g(91%)目标化合物,为无色粉末。ESI-MS(m/e)744[M+H]+.
实施例25制备Boc-Trp-Trp-Met-OBzl
按照实施例6的方法由2.45g(5mmol)Boc-Trp-Trp与2.26g(5.5mmol)Tos·Met-OBzl制得2.28g(64%)目标化合物,为无色粉末。ESI-MS(m/e)712[M+H]+.
实施例26制备Trp-Trp-OBzl
将1.16g(2mmol)Boc-Trp-Trp-OBzl溶于10ml乙酸乙酯中,将反应液置于冰浴下并搅拌,向反应液中加入20ml4N盐酸乙酸乙酯,冰浴搅拌下反应。6h后TLC(二氯甲烷/甲醇,15∶1)检测显示Boc-Trp-Trp-OBzl消失。减压浓缩除去乙酸乙酯,残留物反复加少量乙醚进行减压浓缩以除去氯化氢。最后加少量乙醚将残留物泡洗得1.00g(97%)目标化合物,为无色粉末。ESI-MS(m/e)481[M+H]+.
实施例27制备Trp-Trp-Gly-OBzl
按照实施例26的方法由1.91g(3mmol)Boc-Trp-Trp-Gly-OBzl制得1.53g(95%)目标化合物,为无色粉末。ESI-MS(m/e)538[M+H]+.
实施例28制备Trp-Trp-Ala-OBzl
按照实施例26的方法由1.95g(3mmol)Boc-Trp-Trp-Ala-OBzl制得1.42g(91%)目标化合物,为无色粉末。ESI-MS(m/e)552[M+H]+.
实施例29制备Trp-Trp-Val-OBzl
按照实施例26的方法由2.04g(3mmol)Boc-Trp-Trp-Val-OBzl制得1.67g(96%)目标化合物,为无色粉末。ESI-MS(m/e)580[M+H]+.
实施例30制备Trp-Trp-Ile-OBzl
按照实施例26的方法由2.08g(3mmol)Boc-Trp-Trp-Ile-OBzl制得1.64g(92%)目标化合物,为无色粉末。ESI-MS(m/e)594[M+H]+.
实施例31制备Trp-Trp-Leu-OBzl
按照实施例26的方法由2.08g(3mmol)Boc-Trp-Trp-Leu-OBzl制得1.66g(93%)目标化合物,为无色粉末。ESI-MS(m/e)594[M+H]+.
实施例32制备Trp-Trp-Pro-OBzl
按照实施例26的方法由2.03g(3mmol)Boc-Trp-Trp-Pro-OBzl制得1.58g(91%)目标化合物,为无色粉末。ESI-MS(m/e)578[M+H]+.
实施例33制备Trp-Trp-Phe-OBzl(2g)
按照实施例26的方法由2.18g(3mmol)Boc-Trp-Trp-Phe-OBzl制得1.81g(96%)目标化合物,为无色粉末。ESI-MS(m/e)628[M+H]+.
实施例34制备Trp-Trp-Trp-OBzl
按照实施例26的方法由2.30g(3mmol)Boc-Trp-Trp-Trp-OBzl制得1.94g(97%)目标化合物,为无色粉末。ESI-MS(m/e)667[M+H]+.
实施例35制备Trp-Trp-Glu(OBzl)-OBzl
按照实施例26的方法由2.40g(3mmol)Boc-Trp-Trp-Glu(OBzl)-OBzl制得1.83g(87%)目标化合物,为无色粉末。ESI-MS(m/e)700[M+H]+.
实施例36制备Trp-Trp-Asp(OBzl)-OBzl
按照实施例26的方法由2.36g(3mmol)Boc-Trp-Trp-Asp(OBzl)-OBzl制得1.96g(95%)目标化合物,为无色粉末。ESI-MS(m/e)686[M+H]+.
实施例37制备Trp-Trp-Asn-OBzl
按照实施例26的方法由2.08g(3mmol)Boc-Trp-Trp-Asn-OBzl制得1.62g(91%)目标化合物,为无色粉末。ESI-MS(m/e)595[M+H]+.
实施例38制备Trp-Trp-Gln-OBzl
按照实施例26的方法由2.12g(3mmol)Boc-Trp-Trp-Gln-OBzl制得1.64g(90%)目标化合物,为无色粉末。ESI-MS(m/e)609[M+H]+.
实施例39制备Trp-Trp-Lys(Z)-OBzl
按照实施例26的方法由2.53g(3mmol)Boc-Trp-Trp-Lys(Z)-OBzl制得2.07g(93%)目标化合物,为无色粉末。ESI-MS(m/e)743[M+H]+.
实施例40制备Trp-Trp-Ser-OBzl
按照实施例26的方法由2.01g(3mmol)Boc-Trp-Trp-Ser-OBzl制得1.58g(93%)目标化合物,为无色粉末。ESI-MS(m/e)568[M+H]+.
实施例41制备Trp-Trp-Thr-OBzl
按照实施例26的方法由2.04g(3mmol)Boc-Trp-Trp-Thr-OBzl制得1.57g(90%)目标化合物,为无色粉末。ESI-MS(m/e)582[M+H]+.
实施例42制备Trp-Trp-Tyr-OBzl
按照实施例26的方法由2.23g(3mmol)Boc-Trp-Trp-Tyr-OBzl制得1.81g(94%)目标化合物,为无色粉末。ESI-MS(m/e)644[M+H]+.
实施例43制备Trp-Trp-Met-OBzl(2q)
按照实施例26的方法由2.13g(3mmol)Boc-Trp-Trp-Met-OBzl制得1.74g(95%)目标化合物,为无色粉末。ESI-MS(m/e)612[M+H]+.
实施例45制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Gly-OBzl(3a)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与537mg(1mmol)Trp-Trp-Gly-OBzl制得542mg(65%)目标化合物,为淡黄色粉末。Mp108-109℃.[α]D25=-27.0(c=1.0,丙酮).ESI-MS(m/e)834[M+H]+.IR(KBr)3742.57,3391.15,3310.33,3056.45,2929.12,2847.67,1743.69,1657.05,1518.83,1491.03,1454.33,1343.09,1247.49,1196.93,1097.87,1013.90,968.17,746.48,695.42,579.43,479.69,427.93.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.24(s,1H),10.84(d,J=12.9Hz,2H),8.85-8.64(m,2H),8.58-8.31(m,3H),8.14-7.47(m,10H),7.47-7.17(m,12H),7.10-6.83(m,4H),5.16(s,2H),4.95-4.67(m,2H),4.21-3.82(m,3H),3.32-2.98(m,4H).
实施例46制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Ala-OBzl(3b)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与551mg(1mmol)Trp-Trp-Ala-OBzl制得517mg(61%)目标化合物,为淡黄色粉末。Mp116℃.[α]D25=-24.3(c=1.0,丙酮).ESI-MS(m/e)848[M+H]+.IR(KBr)3738.48,3384.97,3297.16,3055.98,2930.45,2851.76,1738.71,1654.32,1515.55,1499.32,1453.07,1340.29,1247.65,1152.19,1100.97,963.90,746.09,695.53,583.26,478.92,424.41.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.21(s,1H),10.84(d,J=18.3Hz,2H),8.85-8.62(m,2H),8.54(d,J=6.6Hz,1H),8.45(d,J=8.1Hz,1H),8.35(d,J=7.8Hz,1H),8.18-7.48(m,10H),7.48-7.15(m,11H),7.15-6.82(m,4H),5.16(m,2H),4.91-4.68(m,2H),4.60-4.38(m,1H),3.32-2.97(m,4H),1.36(d,J=7.2Hz,3H).
实施例47制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Val-OBzl(3c)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与549mg(1mmol)Trp-Trp-Val-OBzl制得578mg(66%)目标化合物,为淡黄色固体。Mp114-115℃.[α]D25=+23.6(c=1.0,丙酮).ESI-MS(m/e)876[M+H]+.IR(KBr)3746.65,3382.97,3332.72,3065.01,2960.95,2925.31,1736.54,1658.81,1499.50,1455.33,1341.67,1248.42,1148.97,1079.19,1004.77,963.9,898.52,745.90,695.54,612.94,583.88,489.10.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.20(s,1H),10.85(d,J=14.1Hz,2H),8.85-8.27(m,2H),8.47(d,J=8.1Hz,1H),8.34(t,J=7.8Hz,J=8.4Hz,2H),8.09-7.48(m,10H),7.48-7.15(m,11H),7.15-6.80(m,4H),5.16(s,2H),4.95-4.72(m,2H),4.38-4.21(m,1H),3.32-2.95(m,4H),2.31-2.05(m,1H),0.95-0.82(m,6H).
实施例48制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Ile-OBzl(3d)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与593mg(1mmol)Trp-Trp-Ile-OBzl制得560mg(63%)目标化合物,为淡黄色固体。Mp132-133℃.[α]D25=-47.8(c=1.0,丙酮).ESI-MS(m/e)890[M+H]+.IR(KBr)3738.48,3360.11,3255.31,3137.80,3059.39,2961.36,1736.07,1659.14,1519.64,1499.33,1454.92,1188.65,1147.79,1098.75,1011.40,898.52,746.54,695.17,620.66,579.36,481.73,420.55.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.20(s,1H),10.83(d,J=15.0Hz,2H),8.85-8.57(m,2H),8.57-8.21(m,3H),8.14-7.47(m,10H),7.47-7.15(m,11H),7.15-6.80(m,4H),5.15(s,2H),4.95-4.65(m,3H),3.32-2.90(m,4H),2.00-1.85(m,1H),1.50-1.11(m,2H),0.95-0.75(m,6H).
实施例49制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Leu-Obzl(3e)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与3.23g(1mmol)Trp-Trp-Leu-OBzl制得605mg(68%)目标化合物,为淡黄色固体粉。Mp117-118℃.[α]D25=+28.5(c=1.0,丙酮).ESI-MS(m/e).891[M+H]+.913[M+Na]+.IR(KBr)3742.57,3387.06,3307.79,3055.92,2954.77,2864.02,1738.25,1657.61,1499.16,1454.20,1340.15,1247.10,1151.29,1079.81,1004.77,973.97,898.52,745.64,695.10,579.71,477.65.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.21(s,1H),10.85(d,J=13.5Hz,2H),8.88-8.59(m,2H),8.59-8.21(m,3H),8.21-7.48(m,10H),7.48-7.15(m,11H),7.15-6.82(m,4H),5.13(d,J=9.6Hz,2H),4.95-4.54(m,2H),4.53-4.21(m,1H),3.32-2.96(m,4H),1.77-1.35(m,3H),0.98-0.65(m,6H).
实施例50制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Pro-OBzl(3f)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与577mg(1mmol)Trp-Trp-Pro-OBzl制得5.68g(67%)目标化合物,为淡黄色固体。Mp132-134℃.[α]D25=-60.0(c=1.0,丙酮).ESI-MS(m/e)874[M+H]+.IR(KBr)3744.32,3382.97,3323.41,3055.62,2951.46,2868.10,1740.37,1640.78,1557.53,1498.33,1449.46,1343.12,1247.04,1174.54,1096.15,1009.93,968.00,745.73,695.63,583.63,481.73,427.08.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.20(s,1H),10.87(d,J=3.6Hz,2H),8.85-8.47(m,3H),8.37(d,J=7.8Hz,1H),8.08-7.48(m,11H),7.48-7.15(m,12H),7.15-6.85(m,4H),5.14(d,J=1.8Hz,2H),4.95-4.78(m,2H),4.50-4.41(m,1H),3.32-2.95(m,6H),2.30-2.08(m,2H),1.92-1.75(m,2H).
实施例51制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Phe-OBzl(3g)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与627mg(1mmol)Trp-Trp-Phe-OBzl制得5.68g(73%)目标化合物,为淡黄色固体。Mp109-110℃;[α]D 25=-21.5(c=1.0,丙酮).ESI-MS(m/e)924[M+H]+.IR(KBr)3738.48,3387.24,3305.33,3055.84,2925.81,1739.50,1656.66,1453.78,1341.76,1247.35,1097.91,1012.94,959.82,745.66,696.90,579.71,482.58,426.39.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.21(s,1H),10.83(d,J=12.0Hz,2H),8.88-8.65(m,2H),8.47(d,J=8.1Hz,1H),8.36(d,J=9.6Hz,1H),8.12-7.48(m,10H),7.48-7.11(m,17H),7.11-6.82(m,4H),5.07(d,J=4.2Hz,2H),4.92-4.53(m,3H),3.32-2.95(m,6H).
实施例52制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Trp-OBzl(3h)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与666mg(1mmol)Trp-Trp-Trp-OBzl制得693mg(72%)目标化合物,为淡黄色固体。Mp111-112℃.[α]D 25=+19.4(c=1.0,丙酮).ESI-MS(m/e)963[M+H]+.985[M+Na]+.IR(KBr)3746.65,3406.18,3055.03,2924.34,2855.85,1737.82,1657.66,1499.28,1455.01,1342.89,1247.08,1097.27,1012.94,745.15,695.79,582.46,479.05,426.20.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.20(s,1H),10.83(d,J=7.8Hz,2H),8.88-8.85(m,2H),8.56(d,J=15.0Hz,1H),8.46(d,J=8.1Hz,1H),8.33(d,J=11.1Hz,1H),8.09-7.48(m,11H),7.48-6.80(m,20H),5.02(d,J=9.6Hz,2H),4.92-4.58(m,3H),3.32-2.96(m,6H).
实施例53制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Glu(OBzl)-OBzl(3i)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与699mg(1mmol)Trp-Trp-Glu(OBzl)-OBzl制得706mg(71%)目标化合物,为淡黄色固体。Mp96℃.[α]D 25=-48.1(c=1.0,丙酮).ESI-MS(m/e)996[M+H]+.1018[M+Na]+.IR(KBr)3746.65,3374.80,3308.94,3056.19,2929.52,1735.01,1657.46,1519.64,1499.23,1415.38,1339.69,1248.38,1094.67,1009.62,967.47,898.52,746.10,695.90,620.66,579.86,485.89.1H-NMR(300MHz,DMSO-d6)δ/ppm=12.21(s,1H),10.85(d,J=12.9Hz,2H),8.85-8.27(m,5H),8.14-6.81(m,30H),5.23-4.97(m,4H),4.87-4.38(m,3H),3.32-2.85(m,4H),2.33-1.85(m,4H)。
实施例54制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Asp(OBzl)-OBzl(3j)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与685mg(1mmol)Trp-Trp-Asp(OBzl)-OBzl制得736mg(75%)目标化合物,为淡黄色固体。Mp91-92℃.[α]D 25=-19.0(c=1.0,丙酮).ESI-MS(m/e)982[M+H]+.IR(KBr)3746.65,3381.72,3293.08,3055.84,2927.91,1738.02,1658.80,1499.21,1453.04,1380.70,1341.55,1246.98,1096.94,967.88,902.61,745.79,695.79,580.47,477.64,420.43.1H-NMR(300MHz,DMSO-d6):δ/ppm=12.21(s,1H),10.85(d,J=10.8Hz,2H),8.85-8.57(m,3H),8.50(d,J=8.1Hz,1H),8.33(d,J=7.8Hz,1H),8.14-7.47(m,10H),7.47-7.15(m,16H),7.15-6.82(m,4H),5.15(d,J=12.9Hz,4H),4.95-4.65(m,3H),3.32-2.70(m,6H).
实施例55制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Asn-OBzl(3k)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与594mg(1mmol)Trp-Trp-Asn-OBzl制得552mg(62%)目标化合物,为淡黄色固体粉。Mp113.8-134.7℃;[α]D25=-16.67.(c=1.0,丙酮);ESI-MS(m/e):891[M+H]+;IR(KBr):3737.11,3394.73,3277.41,3057.26,2928.88,1729.32,1664.81,1516.83,1454.63,1343.06,1226.51,1098.66,989.45,746.43,698.14,584.40,427.43.1H-NMR(300MHz,DMSO-d6):δ/ppm=12.23(s,1H),10.86(d,J=15.3Hz,2H),8.81-8.35(m,2H),8.16-.7.83(m,3H),7.83-7.48(m,9H),7.48-7.25(m,10H),7.25-6.91(m,8H),5.13(s,2H),4.85-4.68(m,1H),4.68-4.48(m,2H),3.31-2.91(m,4H),2.91-2.81(m,1H),2.71-2.61(m,1H).
实施例56制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Gln-OBzl(3l)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与608mg(1mmol)Trp-Trp-Gln-OBzl制得543mg(60%)目标化合物,为淡黄色固体粉。Mp152.0-153.1℃;[α]D25=+25.45.(c=1.0,丙酮);ESI-MS(m/e):906[M+H]+;IR(KBr):3734.83,3360.10,3056.41,2921.98,1709.61,1661.05,1518.83,1454.91,1342.03,1247.06,1194.69,1096.43,747.36,695.32,582.41,477.10,427.94.1H-NMR(300MHz,DMSO-d6):δ/ppm=12.22(s,1H),10.85(d,J=12.3Hz,2H),8.85-8.66(m,2H),8.66-8.43(m,1H),8.43-8.31(m,2H),8.11-7.48(m,11H),7.48-7.11(m,8H),7.11-6.82(m,6H),5.17(s,2H),4.92-4.61(m,3H),3.31-2.90(m,4H),2.32-2.15(m,2H),2.32-2.15(m,2H),2.00-1.91(m,2H).
实施例57制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-lys(z)-OBzl(3m)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与742mg(1mmol)Trp-Trp-Lys(Z)-OBzl制得612mg(59%)目标化合物,为淡黄色固体粉。Mp108.9-110.3℃;[α]D25=-4.33.(c=1.0,丙酮);ESI-MS(m/e):1039[M+H]+;IR(KBr):3742.57,3387.06,3308.05,3057.66,2933.92,2855.85,1655.52,1520.03,1455.27,1342.41,1249.41,1140.96,1100.24,1012.07,967.99,745.94,697.16,585.55,424.52.1H-NMR(300MHz,DMSO-d6):δ/ppm=12.31(s,1H),10.85(d,J=10.8Hz,2H),8.80-8.52(m,2H),8.52-8.22(m,3H),8.08-7.48(m,9H),7.48-7.12(m,18H),7.12-6.82(m,5H),5.14(s,2H),4.99(s,2H),4.95-4.68(m,2H),4.39-4.21(m,1H),3.23-2.85(m,6H),2.31-1.95(m,2H),1.89-1.55(m,4H)。
实施例58制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Ser-OBzl(3n)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与3.23g(1mmol)Trp-Trp-Ser-OBzl制得535mg(62%)目标化合物,为淡黄色固体粉。Mp115.5-117.0℃;[α]D25=+2.42.(c=1.0,丙酮);ESI-MS(m/e):864[M+H]+;IR(KBr):3741.17,3370.16,3056.27,2931.48,1741.45,1658.77,1498.97,1454.43,1342.30,1244.69,1149.74,1094.78,1042.31,959.82,746.57,695.71,579.80,424.52.1H-NMR(300MHz,DMSO-d6):δ/ppm=12.23(s,1H),10.82(d,J=12.6Hz,2H),8.79-8.64(m,2H),8.52(d,J=4.8Hz,1H),8.36(d,J=4.5Hz,1H),8.05-7.85(m,3H),7.85-7.47(m,10H),7.47-7.21(m,12H),7.11-6.85(m,4H),5.19(d,J=3.6Hz,2H),4.89-4.73(m,3H),4.40-4.29(m,2H),4.10-4.01(m,1H),3.32-3.05(m,4H).
实施例59制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Thr-OBzl(3o)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与581mg(1mmol)Trp-Trp-Thr-OBzl制得570mg(65%)目标化合物,为淡黄色固体粉。Mp118.2-119.6℃;[α]D25=-15.96.(c=1.0,丙酮);ESI-MS(m/e):878[M+H]+;IR(KBr):3736.88,3351.81,3056.23,2930.90,1740.12,1658.47,1499.23,1454.01,1342.10,1246.64,1150.66,1100.48,1008.85,963.90,746.82,695.53,583.88,477.46,420.43.1H-NMR(300MHz,DMSO-d6):δ/ppm=12.20(s,1H),10.82(d,J=9.9Hz,2H),8.90-8.28(m,5H),8.28-7.88(m,4H),7.88-7.48(m,12H),7.48-6.82(m,8H),5.17(s,2H),5.01-4.67(m,3H),4.55-4.39(m,1H),4.30-4.15(m,1H),4.11-3.95(m,1H),3.23-2.95(m,4H),1.22-1.05(m,3H).
实施例60制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Tyr-OBzl(3p)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与3.23g(1mmol)Trp-Trp-Tyr-OBzl制得573mg(61%)目标化合物,为淡黄色固体粉。Mp112.8-113.2℃;[α]D25=+7.00.(c=1.0,丙酮);ESI-MS(m/e):940[M+H]+;IR(KBr):3742.57,3059.58,2931.31,1734.67,1659.32,1513.23,1514.68,1349.57,1246.13,1192.74,1101.27,1008.85,747.62,698.19,592.05,551.19,428.60.1H-NMR(300MHz,DMSO-d6):δ/ppm=12.20(s,1H),10.84(d,J=18.0Hz,2H),9.24(s,1H),8.80-8.22(m,5H),8.22-7.15(m,20H),7.15-6.82(m,6H),6.66(d,J=8.1Hz,2H),5.11(d,J=5.1Hz,2H),4.95-4.65(m,3H),4.65-4.45(m,1H),3.32-2.83(m,6H).
实施例61制备N-(1-苯乙烯基-β-咔啉-3-甲酰基)-Trp-Trp-Met-OBzl(3q)
按照实施例6的方法由345mg(1.1mmol)1-苯乙烯-β-咔啉-3-羧酸与3.23g(1mmol)Trp-Trp-Met-OBzl制得5.68g(95%)目标化合物,为淡黄色固体粉。Mp102.8-103.8℃;[α]D25=+37.08.(c=1.0,丙酮);ESI-MS(m/e):909[M+H]+;IR(KBr):3735.74,3370.72,3304.10,3056.28,2922.39,2847.67,1737.04,1653.70,1517.67,1454.59,1342.61,1248.06,1013.82,967.99,746.02,697.12,586.91,420.67.1H-NMR(300MHz,DMSO-d6):δ/ppm=12.22(s,1H),10.74(d,J=8.7Hz,2H),8.85-8.12(m,5H),8.12-7.49(m,6H),7.49-7.12(m,10H),7.12-6.82(m,4H),5.05(s,2H),4.75-4.35(m,3H),3.11-2.91(m,4H),2.91-2.68(m,2H),2.45-2.022.91(m,4H).
实验例12,3,4,3a-3q的体外细胞毒活性
癌细胞K562、HL-60、HT-29、A549选用RPMI-1640培养基;HepG2选用DMEM培养。其中含10%经灭活的胎牛血清和1×105U·L-1青霉素和100mg·L-1链霉素。
1:贴壁细胞HepG2、HT-29、A549的培养:分别将生长状态良好、处于对数生长期的HepG2、HT-29、A549细胞以5×104个/mL的密度接种于96孔板,每孔100μl,37℃、5%CO2培养箱中培养4小时,按预设的浓度梯度加入待测、经灭菌处理的样品,对照组加入等体积的溶解样品的溶媒。继续培养48小时后,每孔加25μL浓度为5mg/ml的MTT溶液,置于37℃孵育四个小时,小心除去上清液后每孔加入100μl的DMSO(二甲基亚砜),振荡约15min溶解沉淀。立即于酶标仪上检测O.D.(吸光度)值,波长570nm。
2:悬浮细胞HL60、K562的培养:分别将生长状态良好、处于对数生长期的HL-60、K562、细胞以3-5×104个/mL的密度接种于96孔板,每孔100μl,按预设的浓度梯度加入待测、经灭菌处理的样品,对照组加入等体积的溶解样品的溶媒。继续培养48小时后,每孔加25μl浓度为5mg/ml的MTT溶液,继续置于37℃孵育四个小时,离心,3000rpm,5min,小心吸出上清液,每孔加入100μl的DMSO溶解紫色残留物(甲瓒),振荡约15min沉淀全部溶解,于酶标仪上测定O.D.(吸收值),波长570nm。
以下式求出每一个样品浓度下的样品对肿瘤细胞的抑制率:
生长抑制率=[(对照组平均O.D.值一样品组平均O.D.值)/空白组平均O.D.值]×100%,实验重复3次,以抑制率对药物浓度作图,按作图法求出IC50(半数有效抑制浓度)值。结果见表1。
表1化合物2,3,4,3a-q的体外细胞毒活性(IC50±SDμM)
实验例22,4,3a-3q的体内抗肿瘤活性
1)剂量设置
受试化合物设为0.1μmol/kg,阳性对照药设为2μmol/kg,均采用腹腔单次给药。
2)药物配制
受试化合物及阿霉素加入少量的吐温80润湿助溶,逐渐加入生理盐水至所需要浓度即可。
3)给药剂量及给药方案
受试化合物均以腹腔单次给药。按相应的给药剂量每天一次,0.1ml/g,连续给药7天,共给药7次。
阴性对照以等体积的相应溶液,均以腹腔给药。按相应的给药剂量每天一次,0.2ml/g,连续给药7天,共给药7次。
4)动物模型的建立
采用体内抗肿瘤腋皮下接种模型:在无菌条件下抽取接种7d后生长旺盛S180腹水瘤瘤液,用生理盐水稀释成(1∶2)的液体充分混合,将肿瘤细胞悬液用新鲜配制的0.2%台盼蓝染色,混匀后按白细胞计数方法计数,染蓝色者为死细胞,不染色者为活细胞,按如下公式计算细胞浓度和细胞存活率。
细胞浓度=4大方格内活细胞数/4×104×稀释倍数=细胞数/ml
细胞存活率=活细胞数/(活细胞数+死细胞数)×100%
将存活率大于90%的瘤液用匀浆法制备成1×107个/ml的细胞悬液,于相应宿主腋皮下接种0.2ml/鼠,制成实体瘤动物模型。
5)检测指标及方法
a体内神经毒性观察
每日观察给药各组动物的反应小鼠的自主活动、精神状态、毛发、呼吸、饮食,粪便性状。
b实体瘤抑瘤率的测定
各组连续给药7d后,于第8d脱颈椎处死小鼠,称取体重(处死体重),然后用镊子固定小鼠右腋肿瘤生长部位,剪开皮肤,暴露肿瘤,钝性剥离,称重,按如下公式计算抑瘤率。
抑瘤率%=[(阴性对照组平均瘤重-给药组平均瘤重)/阴性对照组平均瘤重]×100%
c脑指数、心指数、肝指数、脾指数和肾指数的测定
采用称重法即剥离肿瘤后的小鼠,再解剖取出脑、心、肝、脾、肾,称取脑重、心重、肝重、肾重、脾重,并按如下公式计算脑指数、心指数、肝指数、脾指数和肾指数。
脑指数(g/kg)=脑重/处死体重。
d统计方法
本实验数据统计均采用t检验和方差分析,以表示。
通过建立移植性小鼠S180肉瘤模型,评价化合物的体内抗肿瘤活性,结果见表2,3。
表2化合物2,4,3a-q体内抗肿瘤实验
注:a)n=12,;b)与生理盐水组比较p<0.01;c)与生理盐水组比较p<0.001;d)与生理盐水组比较p<0.001及与AMD组比较p>0.05;e)与盐水组比较比较p>0.05;f)与2,4组比较p<0.01;
表3化合物0.1μmol/kg剂量下对S180荷瘤小鼠各脏器指标的影响
a)n=12,;b)与生理盐水组比较p<0.05;c)与生理盐水组比较p<0.01;d)与生理盐水组比较p<0.001;
实验例33d的剂量对体内抗肿瘤活性的影响
按照实验例3的实验方法,选取抗肿瘤效果最好的3d考察0.1μmol/kg,0.01μmol/kg和0.001μmol/kg个三浓度下的抗肿瘤活性。结果表明,3d的体内抗肿瘤作用显示浓度依赖性(表4)。
表43d的剂量对体内抗肿瘤活性的影响a
a)n=12;b)与生理盐水组比p<0.001;d)与生理盐水组比p>0.05。
Claims (3)
1.通式I代表的17种化合物
式中AA选自Gly,Ala,Leu,Ile,Phe,Ser,Trp,Glu(OBzl),Thr,Val,Pro,Lys(Z),Asp(OBzl),Gln,Asn,Tyr和Met。
2.权利要求1的通式I代表的17种化合物的制备,该方法由以下步骤构成:
1)在浓盐酸催化存在下Trp-OMe在甲醇中与苯丙烯醛进行Pictet-Spengler缩合生成1-苯乙烯基-1,2,3,4-四氢-β-咔啉-3-甲酯;
2)在浓盐酸催化存在下Trp-OBzl在甲醇中与苯丙烯醛进行Pictet-Spengler缩合生成1-苯乙烯基-1,2,3,4-四氢-β-咔啉-3-苄酯;
3)1-苯乙烯-1,2,3,4-四氢-β-咔啉-3-甲酯在无水THF中与二氯二氰基苯醌芳构化为1-苯乙烯基-β-咔啉-3-甲酯;
4)1-苯乙烯-1,2,3,4-四氢-β-咔啉-3-苄酯在无水THF中与二氯二氰基苯醌芳构化为1-苯乙烯基-β-咔啉-3-苄酯;
5)在二氧六环中将1-苯乙烯基-β-咔啉-3-甲酯皂化为1-苯乙烯基-β-咔啉-3-羧酸;
6)在二氧六环中将1-苯乙烯基-β-咔啉-3-苄酯皂化为1-苯乙烯基-β-咔啉-3-羧酸;
7)在DCC和HOBt存在下Boc-Trp在无水THF中与Trp-OMe缩合为Boc-Trp-Trp-OMe;
8)在甲醇中将Boc-Trp-Trp-OMe皂化为Boc-Trp-Trp;
9)在DCC和HOBt存在下在无水THF中Boc-Trp-Trp分别与Gly-OBzl,Ala-OBzl,Val-OBzl,Leu-OBzl,Ile-OBzl,Pro-OBzl,Phe-OBzl,Trp-OBzl,Ser-OBzl,Thr-OBzl,Lys(Z)-OBzl,Tyr-OBzl,Glu(OBzl)-OBzl,Asp(OBzl)-OBzl,Gln-OBzl,Asn-OBzl,Met-OBzl缩合为Boc-Trp-Trp-Gly-OBzl,Boc-Trp-Trp-Ala-OBzl,Boc-Trp-Trp-Val-OBzl,Boc-Trp-Trp-Leu-OBzl,Boc-Trp-Trp-Ile-OBzl,Boc-Trp-Trp-Pro-OBzl,Boc-Trp-Trp-Phe-OBzl,Boc-Trp-Trp-Trp-OBzl,Boc-Trp-Trp-Ser-OBzl,Boc-Trp-Trp-Thr-OBzl,Boc-Trp-Trp-Glu(OBzl)-OBzl,Boc-Trp-Trp-Lys(Z)-OBzl,Boc-Trp-Trp-Tyr-OBzl,Boc-Trp-Trp-Asp(OBzl)-OBzl,Boc-Trp-Trp-Gln-OBzl,Boc-Trp-Trp-Asn-OBzl,Boc-Trp-Trp-Met-OBzl;
10)在氯化氢-乙酸乙酯溶液中步骤10)中所得的产物分别脱除Boc生成Trp-Trp-Gly-OBzl,Trp-Trp-Ala-OBzl,Trp-Trp-Val-OBzl,Trp-Trp-Leu-OBzl,Trp-Trp-Ile-OBzl,Trp-Trp-Pro-OBzl,Trp-Trp-Phe-OBzl,Trp-Trp-Trp-OBzl,Trp-Trp-Ser-OBzl,Trp-Trp-Thr-OBzl,Trp-Trp-Glu(OBzl)-OBzl,Trp-Trp-Lys(Z)-OBzl,Trp-Trp-Tyr-OBzl,Trp-Trp-Asp(OBzl)-OBzl,Trp-Trp-Gln-OBzl,Trp-Trp-Asn-OBzl,Trp-Trp-Met-OBzl;
11)在DCC和HOBt存在下在无水THF中1-苯乙烯-β-咔啉-3-羧酸分别与步骤10)中所得的产物缩合为1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰甘氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰丙氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰缬氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰亮氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰异亮氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰脯氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰苯丙氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰色氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰丝氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰苏氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰赖氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰酪氨酸苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰谷氨酸双苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰天冬氨酸双苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰谷氨酰胺苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰天冬酰胺苄酯,1-苯乙烯基-β-咔啉-3-甲酰色胺酰色胺酰蛋氨酸苄酯。
3.权利要求1的通式I代表的17种化合物在制备抗肿瘤剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210181086.3A CN103450332B (zh) | 2012-06-01 | 2012-06-01 | 苯乙烯-β-咔啉修饰的三肽苄酯,其制备,抗肿瘤活性和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210181086.3A CN103450332B (zh) | 2012-06-01 | 2012-06-01 | 苯乙烯-β-咔啉修饰的三肽苄酯,其制备,抗肿瘤活性和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103450332A CN103450332A (zh) | 2013-12-18 |
CN103450332B true CN103450332B (zh) | 2016-03-30 |
Family
ID=49733209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210181086.3A Expired - Fee Related CN103450332B (zh) | 2012-06-01 | 2012-06-01 | 苯乙烯-β-咔啉修饰的三肽苄酯,其制备,抗肿瘤活性和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103450332B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105218635A (zh) * | 2014-06-11 | 2016-01-06 | 首都医科大学 | Trp-Trp-Trp五肽修饰的β-咔啉,其制备,纳米结构,活性和应用 |
CN107501391A (zh) * | 2016-06-14 | 2017-12-22 | 首都医科大学 | 1‑取代‑β‑咔啉‑3‑甲酰‑Trp‑Trp‑AA‑OBzl、其合成、活性及应用 |
CN107501392B (zh) * | 2016-06-14 | 2021-06-08 | 首都医科大学 | 1-取代-β-咔啉-3-甲酰-Trp-Trp-Thr-OBzl、其合成及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101597290A (zh) * | 2008-06-04 | 2009-12-09 | 首都医科大学 | β-咔啉-3-甲酰色氨酰氨基酸苄酯及其制备方法和应用 |
CN102146080A (zh) * | 2010-02-10 | 2011-08-10 | 新疆华世丹药业股份有限公司 | β-咔啉碱衍生物类化合物及其应用 |
CN102250202A (zh) * | 2010-05-19 | 2011-11-23 | 首都医科大学 | 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 |
-
2012
- 2012-06-01 CN CN201210181086.3A patent/CN103450332B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101597290A (zh) * | 2008-06-04 | 2009-12-09 | 首都医科大学 | β-咔啉-3-甲酰色氨酰氨基酸苄酯及其制备方法和应用 |
CN102146080A (zh) * | 2010-02-10 | 2011-08-10 | 新疆华世丹药业股份有限公司 | β-咔啉碱衍生物类化合物及其应用 |
CN102250202A (zh) * | 2010-05-19 | 2011-11-23 | 首都医科大学 | 1-对硝基苯基-β-咔啉-3-甲酰氨基酸苄酯及其合成方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103450332A (zh) | 2013-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103159828B (zh) | 1-(4-羟基-3-甲氧羰基)-β-咔啉-3-甲酰色氨酰氨基酸苄酯、其合成及应用 | |
CN103450335B (zh) | β-咔啉酰色氨酰色氨酰氨基酸苄酯、其合成、抗肿瘤作用及应用 | |
CN105218634A (zh) | Yigsr修饰的吲哚喹嗪,其制备,纳米结构,活性和应用 | |
CN105218637A (zh) | Lpniskp修饰的吲哚喹嗪,其制备,纳米结构,活性和应用 | |
CN103450332B (zh) | 苯乙烯-β-咔啉修饰的三肽苄酯,其制备,抗肿瘤活性和应用 | |
CN111848544B (zh) | 可荧光示踪的氨基酸衍生物及其制备方法和应用 | |
CN105198961A (zh) | Rgd修饰的5-氟尿嘧啶,其制备,纳米结构,活性及应用 | |
CN102675416B (zh) | β-咔啉衍生物及其制备方法和应用 | |
CN110152013B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
CN102898502B (zh) | 香豆素衍生物及其制备方法和应用 | |
CN101597289B (zh) | 2-色氨酰-β-四氢咔啉-3-甲酰基氨基酸苄酯及其制备方法和应用 | |
CN101597291A (zh) | 2-(氨基酰色氨酰)-β-四氢咔啉-3-羧酸苄酯及其制备方法和应用 | |
CN107266407B (zh) | 一种响应硝基还原酶杀灭肿瘤细胞的光敏感靶向抗肿瘤前药及其制备方法与应用 | |
CN105218635A (zh) | Trp-Trp-Trp五肽修饰的β-咔啉,其制备,纳米结构,活性和应用 | |
CN105294835A (zh) | Ldv修饰的5-氟尿嘧啶,其制备,纳米结构,活性及应用 | |
CN110418653B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
CN105121447A (zh) | 长春碱类衍生物及其制备方法和应用 | |
CN101497611A (zh) | N-(3-羧基-9-苄基咔啉-1-基)乙基氨基酸,其合成方法及应用 | |
CN106146615A (zh) | 咪唑并吡啶-6-甲酰-氨基酸苄酯,其合成,活性和应用 | |
CN105273053A (zh) | Trp-Trp-Trp十肽修饰的β-咔啉,其制备,纳米结构,活性和应用 | |
CN101497600B (zh) | 2,4,5-三取代-1,3-二硫戊环、其合成方法、其应用 | |
CN105237618A (zh) | 氨基酸苄酯修饰的β-咔啉、合成、纳米结构、活性及应用 | |
CN105315341A (zh) | Trp-Trp-Trp六肽修饰的β-咔啉,其制备,纳米结构,活性和应用 | |
CN105294836A (zh) | Lpniskp修饰的5-氟尿嘧啶,其制备,纳米结构,活性及应用 | |
CN104788498B (zh) | 一种以手性双环二胺为载体配体的铂(ii)配合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160330 Termination date: 20210601 |
|
CF01 | Termination of patent right due to non-payment of annual fee |